Internal Medicine, Hematology & Oncology · Burbank, CA
NPI
1992167076
Since 2016
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2601 W Alameda Ave Ste 300
Burbank, CA, 91505
Phone (818) 806-9020
Groups this clinician bills Medicare through
Medicare paid, 2024
$247K
12,128 services
Medicare patients, 2024
96
Average age 67
Drug cost, 2024
$1.9M
734 prescriptions
Company payments, 2025
$4,171
From 42 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Saghi Esfandiarifard was code J1100 (injection, dexamethasone sodium phosphate, 1 mg), 560 times for 13 patients. In total Saghi Esfandiarifard billed 12,128 services in 64 codes, and Medicare paid $247K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-11-01.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 560 | 13 | $0.09 | $49.67 |
| 96413 Chemotherapy Administration | Office | 47 | 19 | $119.27 | $5,606 |
| 96367 Intravenous Infusion, Hydration | Office | 38 | 16 | $26.17 | $994 |
| 96415 Chemotherapy Administration | Office | 37 | 11 | $25.37 | $939 |
| 99214 Office E&M - Established | Office | 37 | 22 | $101.61 | $3,760 |
| 99442 Telephone Services | Office | 21 | 16 | $44.36 | $932 |
| 99213 Office E&M - Established | Office | 13 | 11 | $61.66 | $802 |
By year: 2022 $9,692 for 2,407 services; 2023 $147K for 11,271 services; 2024 $247K for 12,128 services.
Medicare prescription drug claims, 2024
In 2024, the drug Saghi Esfandiarifard prescribed most often to Medicare patients was Letrozole, with 100 prescriptions and refills. In total Saghi Esfandiarifard wrote 734 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 100 | 191 | 27 | $1,488 |
| Anastrozole Generic | 87 | 180 | 24 | $1,362 |
| Abiraterone Acetate Generic | 47 | 47 | Under 11 | $21K |
| Prednisone Generic | 39 | 49 | Under 11 | $210 |
| Exemestane Generic | 24 | 43 | Under 11 | $4,288 |
| Alendronate Sodium Generic | 23 | 50 | Under 11 | $128 |
| Hydroxyurea Generic | 21 | 41 | Under 11 | $613 |
| Ontruzant Trastuzumab-Dttb | 17 | 17 | Under 11 | $60K |
| Ondansetron Hcl Generic | 17 | 17 | 11 | $370 |
| Perjeta Pertuzumab | 17 | 17 | Under 11 | $105K |
| Imbruvica Ibrutinib | 14 | 14 | Under 11 | $174K |
| Tramadol Hcl Generic | 13 | 13 | Under 11 | $393 |
| Eliquis Apixaban | 13 | 26 | Under 11 | $14K |
| Dexamethasone Generic | 12 | 14 | Under 11 | $269 |
| Eligard Leuprolide Acetate | 12 | 24 | Under 11 | $9,617 |
Brand drugs: 197 claims; generic drugs: 537 claims; opioid claims: 35.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Saghi Esfandiarifard $4,171 ($4,171 in general payments such as food, travel and fees) from 42 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,220.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 25 | $1,220 |
| Merck Sharp & Dohme LLC MRK | 10 | $274 |
| AstraZeneca Pharmaceuticals LP AZN | 8 | $261 |
| E.R. Squibb & Sons, L.L.C. BMY | 16 | $206 |
| Janssen Biotech, Inc. JNJ | 9 | $171 |
| Astellas Pharma US Inc 4503.T | 5 | $143 |
| Daiichi Sankyo Inc. 4568.T | 7 | $136 |
| Incyte Corporation INCY | 4 | $112 |
| Genzyme Corporation SNY | 3 | $99.65 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $88.48 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.